Metastatic hormone-sensitive and castration resistant prostate cancer registry: CAPRI 3.0

Radboud University Medical Center0 sites10,000 target enrollmentTBD

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Not specified
Sponsor: Radboud University Medical Center
Enrollment: 10000
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

2 years ago

Study Type

Observational non invasive

Investigators

Sponsor

Radboud University Medical Center

Eligibility Criteria

Inclusion Criteria

•Patients who were treated in a participating hospital after 01\-01\-2016 and have:
•\- metastatic HSPC, defined as involvement of lymph nodes, bones or viscera on radiological assessment or as defined by either the treating doctor/physician (i.e. palliative treatment with surgical or medical castration)
•\- metastatic CRPC, defined by the treating doctor/physician or the definition of the European Urology Association (EAU)\[10], as prostate cancer that is progressing despite medical or surgical castration (i.e. castrate levels of testosterone (\= 50 ng/dL or \<1\.7 nmol/L)

Exclusion Criteria

Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting

Phase 2

Treatment of patients with castration-resistant metastatic prostate cancer with nuclear medicine procedureCastration resistant metastatic prostate cancer.Malignant neoplasm of prostate

IRCT20180113038331N1Mashhad University of Medical Sciences20

Not yet recruiting

Phase 2

Targeted a-Therapy in Prostate CancerProstate cancer.Malignant neoplasm of prostate

IRCT20210612051548N1Boushehr University of Medical Sciences10

Completed

Not Applicable

Hormonal therapy resistant estorgen receptor positive metastatic breast cancer cohort studyBreast cancer

JPRN-UMIN000019556General Incorporated Association of CSPOR-BC200

Unknown

Phase 3

Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor TherapyBreast Cancer

NCT00688194Gruppo Italiano Mammella (GIM)396

Active, not recruiting

Phase 1

Response evaluation with 68Ga-PSMA PET of metastatic prostate cancer castration resistant patients in treatment with 223RaCl2Patients mCRPC eligible to treatment with 223RaCl2MedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10005993Term: Bone metastasesSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: LLTClassification code 10036223Term: Positron emission tomographySystem Organ Class: 100000004848MedDRA version: 21.1Level: PTClassification code 10062904Term: Hormone-refractory prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]

EUCTR2017-001395-38-ITAZIENDA USL DELLA VALLE D'AOSTA50